Given Imaging (NASDAQ:GIVN)’s Studies Verify, PillCam ESO as A Tool Help Triage Patients- GIVN, BSX, MDT, HOLX, STJ, SYK, ZMH

Given Imaging Ltd. (NASDAQ:GIVN), a world leader in specialty GI products and pioneer of capsule endoscopy, declared on Monday that novel studies verify the value of its PillCam ESO as a tool to assist triage patients with upper gastrointestinal bleeding (UGIB) and explain that PillCam ESO can detect lesions that traditional gastroscopy has missed.

An extra new study demonstrates that Bravo pH monitoring for patients with gastroesophageal reflux disease (GERD) can be expanded to 4 days to surge findings.

This longer duration will result in more significant feedback regarding patients’ conditions and how they are affected by daily activities, permitting doctors to work with patients to adjust their diet and drug regimens. The data from these studies were obtainable at Digestive Disease Week (DDW), being held from May 19-22, 2012, in San Diego.

Sector analysis, overall healthcare sector moved down, Boston Scientific Corporation (NYSE:BSX) small declined -2.30%, Medtronic, Inc. (NYSE:MDT) lost -0.30%, Hologic, Inc. (NASDAQ:HOLX) moved down -1.30%, St. Jude Medical, Inc. (NYSE:STJ) dropped -0.52%, Stryker Corporation (NYSE:SYK) which also decreased -1.41% and Zimmer Holdings, Inc. (NYSE:ZMH) fell -1.08%.

Given Imaging Ltd. (NASDAQ:GIVN) after opening at $17.42 hit high price of $17.50 and then closed at $17.29 by plunging -0.29% and on last session volume of 54,453.00 shares was surprisingly lower than its average volume of 67,242.00 shares.

The stock price volatility was 2.14% for a week and 2.19% for a month as well as price volatility’s Average True Range for 14 days was 0.42 and its beta remained 1.42.

The liquidity measure in recent quarter results of the company was recorded 4.28 as current ratio and on the other side the debt to equity ratio and long-term debt to equity ratio also remained at flat. The Company had total cash at hand $76.00 million and a book value per share as $6.53 in the most recent quarter.

GIVN generated revenue of 179.83 million in the following twelve months and earned $11.50 million. The Company showed a positive 6.40% in the net profit margin and as well as in its operating margin which remained 6.64%. Company’s annual sales growth for the past five year was 13.37%.


DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.